David Henderson, former founding executive member of Oscar Health, has been appointed as Chief Executive Officer of DayTwo.  He joins to further scale the company and expand solutions for employers, health plans, and health systems.

“We are extremely excited to have Dave’s leadership and talents,” said Yair Briman, Chairman of the Board. “He has an outstanding track record of dramatically scaling digital healthcare companies who then become innovators and disruptors.” 

DayTwo also announced $37 million in new funding to accelerate its expansion of chronic disease interventions. DayTwo’s virtual care solution currently treats metabolic diseases like diabetes, prediabetes, and obesity, which affects 1 in 2 US adults.

“I’m thrilled to be joining a unique and innovative company that is helping people live healthier lives and manage their chronic conditions,” said David Henderson, CEO of DayTwo. “The company employs the most advanced microbiome analysis in the world, resulting in groundbreaking clinical discoveries and life-saving disease interventions. With the world’s largest and richest proprietary gut microbiome dataset, DayTwo has tremendous opportunities to apply its science and IP to improve outcomes for other diseases in addition to diabetes, prediabetes, and obesity. I look forward to building on the incredible success of the company and working closely with our innovative clients and partners.”

DayTwo participants continue to see outstanding results in controlling their blood sugar, reducing their A1C, and improving their Time- In- Range, which is the time a participant stays in healthy blood sugar range, an important measure of health. Participants in DayTwo’s programs also see vast improvements in sleep and energy, and reductions in stress and hunger. 

“Given the staggering crisis related to metabolic disease, DayTwo’s unique and extensible, science-based solution is creating enormous value by solving healthcare and cost challenges, in ways never before imagined,” said Jacky Abitbol, Managing Partner of Cathay Innovation. “We leverage our global platform to back and scale technologies…where companies like DayTwo have the potential to positively impact millions of lives. Their program represents the future of disease care, nutrition and beyond.” 

“We are proud of our long-term partnership with DayTwo since its founding. The company has made huge strides and is driving substantial value and meaningful clinical results with employers, health plans, and health systems. We are excited to be a part of this next rapid-growth stage of DayTwo’s commercial success,” said Yair Schindel, M.D., Co-Founder & Managing Partner, aMoon.

“We are thrilled to support DayTwo and its pioneering solutions for metabolic disease using precision nutrition through microbiome science. This fits with our philosophy of investing in groundbreaking healthcare technologies that contribute to humanity and have a positive impact on the world,” said Gayathri Radhakrishnan, Director, Venture Capital AI Fund, Micron Technology. 

What DayTwo’s precision nutrition solution means for employers: 

  • Sustainable engagement that lowers costs 
  • Better physical & mental health outcomes
  • Improved productivity for employees

About DayTwo

DayTwo, the leader in precision nutrition with the world’s most advanced proprietary microbiome science, offers a sustainable path to remission for metabolic diseases (diabetes, prediabetes, and clinical obesity). Metabolic disease is the first condition to be addressed by DayTwo’s microbiome discovery platform. Their scientific research is cited by the National Institutes of Health as a foundational element in its 10 year, $150 million strategic plan for precision nutrition.

The company’s solution includes gut microbiome profiling, artificial intelligence to predict blood sugar response to foods, and dedicated virtual care. The company’s results set a new national benchmark for diabetes and metabolic disease care—with significant sustained clinical results in reducing A1C, improving Time in Range, and reducing or eliminating prescription medications. DayTwo’s scientific research is cited by the National Institutes of Health as a foundational element in its 10 year, $150 million strategic plan for precision nutrition.



Related Posts